Clobazam%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252528oral%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520formulation%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252529

## Clobazam (Oral Formulation) ### Overview Clobazam is a 1,5-benzodiazepine with anticonvulsant properties. It has a longer half-life and a different metabolic profile compared to traditional 1,4-benzodiazepines. ### Primary Indications Adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome (LGS) in patients 2 years of age and older. ### Adult Dosing * **LGS:** Initial dose: 5 mg twice daily. Increase by 5 mg every week. Usual maintenance dose: 10 mg twice daily. Maximum recommended dose: 20 mg twice daily. ### Pediatric Dosing (2 years and older) * **LGS:** Initial dose: 5 mg twice daily. Increase by 5 mg every week. Usual maintenance dose: 10 mg twice daily. Maximum recommended dose: 20 mg twice daily. ### Dose Adjustments * **Hepatic Impairment:** Use with caution. No specific dose adjustments are established, but lower doses may be warranted due to potential for reduced clearance. * **Renal Impairment:** Use with caution. No specific dose adjustments are established, but lower doses may be warranted. * **Concomitant Medications:** Consider interactions with CYP3A4 inhibitors or inducers, and other CNS depressants. ### Contraindications * Known hypersensitivity to clobazam or other benzodiazepines. ### Adverse Effects * **Common:** Somnolence, sedation, gait disturbance, fatigue, drooling, constipation, increased appetite, aggression, irritability, upper respiratory tract infection, vomiting, diarrhea. * **Serious:** Suicidal behavior and ideation, severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis), respiratory depression, withdrawal symptoms (including rebound seizures). ### Key Drug Interactions * **CNS Depressants (e.g., alcohol, opioids, other benzodiazepines, sedating antihistamines):** Additive CNS depressant effects. * **CYP3A4 Inhibitors (e.g., ketoconazole, itraconazole, ritonavir):** May increase clobazam plasma concentrations. * **CYP3A4 Inducers (e.g., carbamazepine, phenytoin, rifampin):** May decrease clobazam plasma concentrations. * **Phenytoin:** Clobazam can increase phenytoin levels. Monitor phenytoin levels. * **Valproic Acid:** Co-administration may increase valproic acid levels. Monitor valproic acid levels. ### Monitoring * Monitor for efficacy in seizure control. * Monitor for adverse effects, especially somnolence, sedation, and behavioral changes. * Monitor for signs of suicidal behavior or ideation. * If co-administered with phenytoin or valproic acid, monitor their serum concentrations. * Monitor for withdrawal symptoms upon discontinuation. ### Clinical Pearls * Clobazam has a longer half-life which allows for less frequent dosing compared to some other benzodiazepines. * Taper gradually upon discontinuation to avoid withdrawal symptoms. * Due to the risk of somnolence, caution patients about driving or operating heavy machinery. * Risk of severe skin reactions requires immediate discontinuation if signs or symptoms develop. *** *Disclaimer: This information is intended for healthcare professionals. Always consult the most current prescribing information and local protocols before making clinical decisions.*